Sadhana Jackson

Dr. Sadhana Jackson


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2017 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
MMMatthew McCord
Matthew McCord
YMYoh-Suke Mukouyama
Yoh-Suke Mukouyama
MGMark R. Gilbert
Mark R. Gilbert
SJSadhana Jackson
Sadhana Jackson
The WNT signaling pathway has been of great interest to developmental biologists for decades and has more recently become a central topic for study in cancer biology. It is vital for cell growth and regulation of embryogenesis in many organ systems, particularly the CNS and its associated vasculature. We summarize the role of WNT in CNS development and describe how WNT signaling makes key contributions to malignant glioma stemness, invasiveness, therapeutic resistance, and angiogenesis. The role of WNT in these mechanisms, along with creation and maintainance of the blood-brain barrier (BBB), points to the potential of WNT as a multi-faceted target in malignant glioma therapy.

1 September 2019 in Biomaterials
Verified
Journal Article
Closed access
SJSadhana Jackson
Sadhana Jackson
CMCaitlin Meeks
Caitlin Meeks
AVAmélie Vézina
Amélie Vézina
RRRobert W. Robey
Robert W. Robey
KTKandice Tanner
Kandice Tanner
MGMichael M. Gottesman
Michael M. Gottesman

15 January 2018 in Fluids and Barriers of the CNS
Verified
Journal Article
Open access
PDF file
SJSadhana Jackson
Sadhana Jackson
JWJon Weingart
Jon Weingart
ENEdjah K Nduom
Edjah K Nduom
THThura Harfi
Thura Harfi
RGRichard T. George
Richard T. George
SGStuart A. Grossman
Stuart A. Grossman
The blood–brain barrier (BBB) severely limits the entry of systemically administered drugs including chemotherapy to the brain. In rodents, regadenoson activation of adenosine A2A receptors causes transient BBB disruption and increased drug concentrations in normal brain. This study was conducted to evaluate if activation of A2A receptors would increase intra-tumoral temozolomide concentrations in patients with glioblastoma. Patients scheduled for a clinically indicated surgery for recurrent glioblastoma were eligible. Microdialysis catheters (MDC) were placed intraoperatively, and the positions were documented radiographically. On post-operative day #1, patients received oral temozolomide (150 mg/m2). On day #2, 60 min after oral temozolomide, patients received one intravenous dose of regadenoson (0.4 mg). Blood and MDC samples were collected to determine temozolomide concentrations. Six patients were enrolled. Five patients had no complications from the MDC placement or regadenoson and had successful collection of blood and dialysate samples. The mean plasma AUC was 16.4 ± 1.4 h µg/ml for temozolomide alone and 16.6 ± 2.87 h µg/ml with addition of regadenoson. The mean dialysate AUC was 2.9 ± 1.2 h µg/ml with temozolomide alone and 3.0 ± 1.7 h µg/ml with regadenoson. The mean brain:plasma AUC ratio was 18.0 ± 7.8 and 19.1 ± 10.7% for temozolomide alone and with regadenoson respectively. Peak concentration and Tmax in brain were not significantly different. Although previously shown to be efficacious in rodents to increase varied size agents to cross the BBB, our data suggest that regadenoson does not increase temozolomide concentrations in brain. Further studies exploring alternative doses and schedules are needed; as transiently disrupting the BBB to facilitate drug entry is of critical importance in neuro-oncology.

21 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DADavis P. Argersinger
Davis P. Argersinger
SRSarah Renae Rivas
Sarah Renae Rivas
ASAshish Harish Shah
Ashish Harish Shah
SJSadhana Jackson
Sadhana Jackson
JHJohn David Heiss
John David Heiss
H3K27M-mutant diffuse midline gliomas (DMGs) are rare childhood central nervous system tumors that carry a dismal prognosis. Thus, innovative treatment approaches are greatly needed to improve clinical outcomes for these patients. Here, we discuss current trends in research of H3K27M-mutant diffuse midline glioma. This review highlights new developments of molecular pathophysiology for these tumors, as they relate to epigenetics and therapeutic targeting. We focus our discussion on combinatorial therapies addressing the inherent complexity of treating H3K27M-mutant diffuse midline gliomas and incorporating recent advances in immunotherapy, molecular biology, genetics, radiation, and stereotaxic surgical diagnostics.

24 May 2017 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
SJSadhana Jackson
Sadhana Jackson
AEAyman ElAli
Ayman ElAli
DVDaniela Virgintino
Daniela Virgintino
MGMark R Gilbert
Mark R Gilbert
The pericyte, a constitutive component of the central nervous system, is a poorly understood cell type that envelops the endothelial cell with the intended purpose of regulating vascular flow and endothelial cell permeability. Previous studies of pericyte function have been limited to a small number of disease processes such as ischemic stroke and Alzheimer’s disease. Recently, publications have postulated a link between glioma stem cell differentiation and pericyte function. These studies suggest that there may be an important interaction of pericytes with tumor cells and other components of the tumor microenvironment in malignant primary glial neoplasms, most notably glioblastoma. This potential cellular interaction underscores the need to pursue more investigations of pericytes in malignant brain tumor biology. In this review, we summarize the functional roles of pericytes, particularly focusing on changes in pericyte biology during response to immune cells, inflammation, and hypoxic conditions. The information presented is based on the available data from studies of pericyte function in other central nervous system diseases but will serve as a foundation for research investigations to further understand the role of pericytes in malignant gliomas.

23 October 2024 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
MLMary Jane Lim-Fat
Mary Jane Lim-Fat
JBJulie Bennett
Julie Bennett
QOQuinn Ostrom
Quinn Ostrom
MTMehdi Touat
Mehdi Touat
EFEnrico Franceschi
Enrico Franceschi
KYKee Kiat Yeo
Kee Kiat Yeo
Adolescents and young adults (AYAs; ages 15–39 years) are a vulnerable population facing challenges in oncological care, including access to specialized care, transition of care, unique tumor biology, and poor representation in clinical trials. Brain tumors are the second most common tumor type in AYA, with malignant brain tumors being the most common cause of cancer-related death. The 2021 WHO Classification for central nervous system (CNS) Tumors highlights the importance of integrated molecular characterization with histologic diagnosis in several tumors relevant to the AYA population. In this position paper from the Society for Neuro-Oncology (SNO), the diagnosis and management of CNS tumors in AYA is reviewed, focusing on the most common tumor types in this population, namely glioma, medulloblastoma, ependymoma, and CNS germ cell tumor. Current challenges and future directions specific to AYA are also highlighted. Finally, possible solutions to address barriers in the care of AYA patients are discussed, emphasizing the need for multidisciplinary and collaborative approaches that span the pediatric and adult paradigms of care, and incorporating advanced molecular testing, targeted therapy, and AYA-centered care.